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ThlS Study. estlmated the late gastrolnteStinal (GI) toxIClty after three-dlmenSIOnal conformal radlOtherapy
(3DCRT) with curative intent for localized prostate cancer (LPC) and assessed the correlated clinical factors.
88 LPC patients underwent 3DCRT between March 2004 and May 2007. The total dose was 74 Gy ln 2-Gy
dally fractions for each patient. The medlan patient age was 71 years (range 52-8O)･ According to the National
ComprehenslVe Cancer Network (NCCN) rlSk group classification, 6, 45, and 37 patients were low, intermediate,
and high rlSk, respectively. There were 39, 34, and 15 patients at stages Tl to T3, respectively. Fifty six pa-
tients were given androgen deprivation therapy (ADT). There was coexisting hypertension (HT) in 17 pa-
tients, diabetes mellitus (DM) in 10, hemorrhoids in 9, and pre-existing gastrointestlnal (GI) dlSeaSe in 13.
Four patients had undergone previous abdominal surgery. , Twelve patients received anticoagulants/antiaggre-
gants (A/A) for pre-existing vascular disease. The relationships between the followlng Variables and late GI
toxIClty Were aCCeSSed : NCCN risk, use of ADT presence of HT DM, hemorrhold, pre-exIStlng GI dlSeaSe, A/A
treatment, and history of abdomlnal surgery. Late GI toxiclty Of grade 2 and 3 Occurred in one patient each.
There was no grade 4 0r higher late toxiclty. Late GI toxiclty Ofgrade 2 or 3 at 3 years occurred in 3%. In
univariate analysis, AノA treatment and pre-existing GI dlSeaSe Were SignlflCantly correlated with grade 2 or 3
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late GI toxicity. A/A treatment and pre-existing GI disease appear to predict grade 2 or 3 late GI toxicity.
Introduction
Dose escalation of radiotherapy (RT) improves.
the treatment outcome of localized prostate cancer
(LPC)1~3). However, late toxicity may limit the ex-
tent to which the dose may be escalated safely.
The essential dose-limitlng Organs in external beam
radiotherapy (EBRT) for LPC are the rectum and
bladder.
Several publications have described the clinical fac-
tors related to late gastrointestinal (GI) toxicity4~11).
However our ･previous report analyzed heteroge-
neous group lnCluding both intenslty-modulated ra-
diotherapy (IMRT) group and three-dimensional
conformal radiotherapy (3DCRT) groupll).
In this study, we assessed clinical variables, In-
cluding treatment with anticoagulants/antiaggre-
gants, in relation to late GI toxicity grade 2 0r worse
in LPC patients who underwent curative 3DCRT
Materials and Methods
Between June 2004 and May 2007, a total of 96
patients with clinically LPC were treated with
3DCRT. 8 0f those patients were excluded from
this analysis because of insufficient observation
period. 88 patients were included in this study･
Patient characteristics are shown in Table 1. Pa-
tients were classified into low-, intermediate-, and
high-risk groups based on the NationalComprehensive
Cancer Network (NCCN) risk group classification.
American Joint Committee on Cancer clinical T
stage was used. Twelve patients (14%) had re-
ceived anticoagulants/antiaggregants before, during,
and after radiotherapy (RT) for cardiovascular or
cerebrovascular disease. The Eastern Cooperative
Oncology Group performance status (PS) during ra-
diotherapy period was as follows･ PS-0 in 82 pa-
tients, and PS-1 in 6. There was no PS-2 or
-104
higher patients in this series. Details of pre- or co-
existing GI disease were as follows : colon polyps in
5 patients, gastric ulcer in 3, gastric cancer in 2, co-
lon cancer in 1, enteritis in 1 and diverticulitis in 1.
Presence of hemorrhoids was in 9. The consent of
all patients was obtained before the study was car-
ried out.
Radioth raPy : In planning 3DCRT, Eclipse
(release 6.5 ; Varian Medical Systems, Palo Alto,
CA) was used for dose calculations. The daily dose
was 2.0 Gy per fraction, administered 5 days a week･
The prescribed total dose for each patient was 74 Gy･
All patients reated with 3DCRT were immobi-
1bble 1. Patient characteristics.
〃-88 (%)
Median age (range)(years)　　　　　　　　71 (52-80)
NCCN risk group Low　　　　　　6 ( 7)
Intermediate　　45 (51)
High　　　　　37 (42)
Clinical T stage T1　　　　　39 (44)
T2　　　　　　　34 (39)
T3　　　　　　15 (17)
Use of ADT Yes　　　　　　　56 (64)
No　　　　　　　32 (36)
Presence of hypertension Yes　　　　　17 (19)
No　　　　　　　71 (81)
Presence of diabetes mellitus Yes 10 (ll)
No　　　　　　　78 (89)
Presence of GI diseas  Yes　　　　　　13 (15)
No　　　　　　　75 (85)
Presence of hemorrhoid Yes　　　　　　　　9 (lO)
No　　　　　　　79 (90)
Prior abdominal surgery Yes　　　　　　4 ( 5)
No　　　　　　　84 (95)
Use of A/A Yes　　　　　　12 (14)
No　　　　　　　76 (86)
NCCN-national comprehenslVe Cancer network ; ADT
-androgen deprlVat10m therapy ; GI-gastrointertinal ;
A/A - antlCOagulants/antiaggregants
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1ized in the suplne position with a vacuum bag sys-
tem for their feet. CT scans were performed at 3-
to 5-mm slice thickness uslng a multi-detector CT
scanner (GE Light Speed QXi). Patients were in-
structed to urinate Just before CT scannlng and be-
fore every treatment fraction. The clinical target
volume (CTV) was expanded in three dimensions
with 0.7- to 1.0-cm marglnS tO Obtain the plannlng
target volume (PTV), except at the prostate-rectum
interface, where a 0.3-cm margln Was adopted to de-
crease rectal involvement. The dose was specified
according to the International Commission on Radia-
tion Units and Measurements reference polnt and
was delivered with 10-MV photons in fractions of
2.0 Gy.
After the treatment plannlng, One palr Of orthogo-
nal (anteroposterior (AP) and right-lateral) digitally
reconstructed radiograph (DRR) was constructed in
which the position of bony anatomy could be located･
This image set constituted the reference image pair.
For the verification of treatment fields on each RT
day, the theraplSt acquired one palr Of orthogonal
electronic portal images (EPI) using the AP and left-
right (LR) set-up fields ; these constituted the
comparison image set. The portal images were
taken uslng a Varian Oncology Systems an amor-
phous silicon flat-panel electronic portal imager
(Varian MedicalSystems, Palo Alto, CA) mounted on
a dualenergy Clinac 2100EX accelerator. The daily
repositionlng Of the patients before each treatment
fraction was accomplished through image matching
of the EPI to the reference DRR based on bony
anatomy.
Follow-uP : Follow-up evaluations after treatment
were performed at intervals of 3-6 months for 5
years and every 6 months thereafter. The follow-
up period ranged from 5 to 47 months (median, 23)･
ToxIClty SCOnng : Late toxiclty appeared more
than or equal to 90 days after the initiation of EBRT
and was scored according to the Radiation Therapy
Oncology Group/European Organization for Re-
search and Treatment of Cancer (RTOG/EORTC)
morbidity sc es16･17)･ In brief as for GI toxiclty,
moderate diarrhea and colic, bowel movements of
more than 5 tim s daily, excessive rectal mucus, Or
intermittent blee ing was considered grade 2 mor-
bidity, and any lase  cauterization or blood transfu-
sion resulting from rectal bleeding was considered
grade 3 toxiclty.
Statistical analys s : The primary endpoint was
grade 2 0r higher lat  GI toxiclty. The complication
rates were determined uslng Kaplan-Meier estimates.
The ti e to grade 2 0r worse late GI toxicity were
fit to log-rank tes s estimating the clinical variables
including presence of hypertension, presence of dia-
betes mellitus, NCCN risk group classification, use
of androgen dep ivation therapy (ADT), presence of
pre- or co-existlng GI disease, presence of hemor-
rhoid, history of abdominal surgery, and treatment
with anticoagu ants/antiaggregants. Statistical
analyses w re perbrmed uslng the Statistical Pack-
ag  for Social Sciences, version ll･0, for Windows･
AP<0.05 significance level (2-sided) was considered
forall statistic ltests.
Results
Late GI toxicity of grades 2 and 3 Occurred in one
pa ie t each. No patient developed grade 4 0r
higher late GI and GU toxicity. Late GI toxiclty Of
grade 2 or3 at 3 years occurred in 3%･ The median
tim  to d veloplng grade 2 or 3 late GI toxiclty Was
12 months (range, 9-14). In univariate analysis,
treatment with a ticoagulants/antiaggregants corre-
1ated with grade 2 or 3 late GI toxiclty, aS pre- Or CO-
ex stlng GI dis se did, whereas presence of hyper-
tension, presence of diabetes mellitus, presence of
hemorrhoid, NCCN risk group, prlOr abdominal sur-
gery, and use ofADT were not (Table 2)･ Among
those patients who used anticoagulants/antiaggre-
gants, the 3-year incidence of late GI grade 2 or 3
was 19%, compared with O% for those who did not
receive nticoagulants/antiaggregants (P- 0.0006).
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Table 2. Univariate analysis results for Grade 2 or3
1ate GI toxicities
Factors ?f?VR?
NCCNriskgroup ??R?
UseofADT ?縱b?
Hypertension ?紊?
Diabetesmellitus ??c?
Hemorrhoid ?縱?
Pre-orco-eXistingGⅠdisease ???R?
Priorabdominalsurgery ?縱B?
Anticoagulants/antiaggregants ???b?
NCCN-national comprehenslVe Cancer network ; ADT
- androgen deprlVation therapy ; G1 - gastrointertinal
Discussion
ln current study, treatment with anticoagulants/
antlaggregantS correlated significantly with grade 2
or 3 late GI toxicity after definitive 3DCRT for local-
ized prostate cancer, as did pre- or co-existing GI
disease, although the other clinical variables were
not related statistically. However, it was difficult to
ascertain whether the other co-existing morbidities
did not have relationship to late GI toxiclty Or not,
because our assessment was retrospective study.
Some studies have reported that several clinical
factors are related to late GI toxicity. According to
Liu et aL6), Coexisting GI disease increased the risk
of late grade 2 or 3 GI toxicities as well as our
report. skwarchuk et al･4) and Herold et al･7) have
reported that diabetes was correlated with late GI
toxiclty. Several authors have identified the pres-
ence of acute GI toxiclty aS a Slgnificant factor for
late GI toxiclty4~仰), and some havealSo described
an association between use of hormonal therapy
(HT) and late GI toxicity5･6rl｡). In contrast, like us,
Zelefsky et al･9) Could not identify any relationship
between HT and late GI toxiclty.
To our knowledge, there are few reports about the
relationship between the use of anticoagulants/anti-
aggregants and late GI toxiclty. In the present
study, treatment with anticoagulants/antiaggregants
was slgnificantly correlated with grade 2 or 3 late GI
toxicity. According to Choc etal.12), patients on an-
ticoagulants were at substantial risk for acute or late
bleeding after EBRT for prostate cancer, and the au-
thors suggested that surgery might be preferable to
RT in these patients. They also suggest that lower
RT doses or smaller target volumes should be con-
sidered for patients who are not surglCal candidates.
However, With a lower RT dose or smaller target
volume, intermediate- or high-risk patients may not
obtain a satisfactory outcome. Furthermore, in the
study by Ch e etal･12), the patients and treatment
appeared to be heterogeneous ; one patient received
a seed implant after 45 Gy ; six were treated after
radical prostatectomy ; and the treatment field in-
cluded the prostate and seminal vesicles for 30 pa-
tients and the whole pelvis for three patients. In
their other publicationln, choc etal･ reported that
patients taking anticoagulation therapy have a sub-
sta ti risk of ble ding toxicity from EBRT. How-
er, heir patientsalso seemed to be heterogeneous
in order to include 3DCRT patients group and IMRT
patients group, as well as our previous studyll)･ A1-
thoughVavassori et al.14) have studied the correla-
tion betw en acute GI toxicity and the use of antico-
agulants/antiaggregants, HT, and mean rectal
radiation dose, they have not reported late GI
toxiclty. In a study based on a questionnaire sur-
veⅥ Fiorino et al･15) have shown that the use of anti-
Coagulants/antiaggregants had no significant rela-
tionship to grade 2 and 3 late GI toxicities.
HoweveI; questionnaire-assessed toxicity may not
correlatewith RTOG/EORTC toxicity.
choe et al.1H) demonstrated that the use of antico-
agulation therapy lS associated with improved PSA
control in patients with LPC who receive RT The
potential benefit may be pronounced in patients with
high-risk di e se bu  no overt evidence of metastasis.
However, the use of anticoagulants is associated
with an elevated risk of bleeding complications,
which may be even more slgnificant in patients with
cance . Therefore, according to them, the risk of
-1O6-
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serious bleeding must be weighed agalnSt the poten-
tial benefit. Additional studies investigating new
anticoagulants with lower bleeding risk will be nec-
eSSary･
Preexistlng Vascular disease might have caused
grade2 or 3 late GI toxicities as main reason.
Simizu et al･19) reported late laryngeal radionecrosis
in severe arteriosclerosis. They considered gener-
al vascular condition of the patient to increase the
rate and degree of development of radionecrosis･
However, the use of anticoagulants/antiaggregants
might have promoted late GI toxiclty ln addition to
preexistlng general vascular condition. As limit of
the current study, it was difficult to clarify which
vascular disease needed anticoagulants/antiaggre一
gants or the medication of anticoagulants/antiaggre-
gants promoted grade 2 or 3 late GI toxicities. In
addition, the current number of patients was so
small that it is difficult to show significant relation-
ship between late GI toxicities and the use of antico-
agulants/antiaggregants. Further investigation is
needed to confirm the relations.
In conclusion, general vascular disease treated
with anticoagulants/antiaggregants and presence of
pre- or co-existlng GI disease appear to be correlat-
ed with grade 2 or 3 late GI toxicities after 3DCRT
for LPC. Watchful follow-up of patients treated
with anticoagulants/antiaggregants after EBRT may
be necessary.
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